Client News

Posted: March 2, 2015, 11:09 pm
[AP] - A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: Tonix Pharma rose 26.5 percent to $7.40. Trillium Therapeutic rose 16.4 percent to $11.12. Ebix Inc. rose 14.3 percent to ...
Posted: March 2, 2015, 11:08 pm
[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...
Posted: March 2, 2015, 11:08 pm
[GlobeNewswire] - NEW YORK -- NeoStem, Inc. ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based personalized medicine therapies, announced today 2014 year end results ...
Posted: March 2, 2015, 9:01 pm
[at noodls] - 6th Annual Leaders in Health Care Awards Competition Evaluated Nearly 80 Companies For Excellence in Innovation and Impact BOTHELL, WA - March 2, 2015 - BioLife Solutions, Inc. (NASDAQ: BLFS), a leading ...
Posted: March 2, 2015, 7:12 pm
[PR Newswire] - The allowed patent claims cover DelMar's novel methods and compositions for the utility of chemical agents, compounds, and dosage forms related to administering VAL-083 (dianhydrogalactitol) for the treatment of hyperproliferative diseases, including cancer, to improve efficacy and reduce side effects of previously suboptimal chemotherapeutic agents. "This is the very first patent application filed when we recognized the broad potential of VAL-083, a drug candidate that has demonstrated promising results in multiple cancer indications in previous clinical trials sponsored by the U.S. National Cancer Institute," commented Jeffrey Bacha, DelMar's president and CEO.
Posted: March 2, 2015, 4:17 pm
[PR Newswire] - TEL AVIV, Israel, March 2, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization ...
Posted: March 2, 2015, 1:30 pm
Posted: March 2, 2015, 12:57 pm
[at noodls] - Download PDF Rapid Resolution in SHRM Correlates With Early Improvements in Visual Acuity Observed in Phase II IMPACT Study in Wet AMD NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. ...
Posted: March 2, 2015, 12:57 pm
[GlobeNewswire] - NEW YORK -- Ohr Pharmaceutical, Inc. , an ophthalmology research and development company, today announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society ...
Posted: March 2, 2015, 12:30 pm
[CNW Group] - Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease
Posted: March 2, 2015, 11:02 am
[PR Newswire] - The objectives of the Phase 2 clinical study ("Harmony AD Study") are to evaluate the efficacy, safety and tolerability of ELND005 over 12 weeks of treatment in patients with mild to severe AD, who are experiencing at least moderate levels of agitation/aggression. The randomized, double-blind, placebo-controlled study has enrolled 350 AD patients at 69 clinical sites in the United States, Canada, Spain and the United Kingdom. The primary efficacy endpoint of the study is the change from baseline in the Neuropsychiatric Inventory – Clinician ("NPI-C") scale of agitation and aggression. It is anticipated that the top-line data from the Harmony AD Study will be announced mid-year 2015.
Posted: March 2, 2015, 11:02 am
[PR Newswire] - BOTHELL, Wash., March 2, 2015 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation ...
Posted: March 2, 2015, 11:00 am